GNMK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNMK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GenMark Diagnostics's change in receivables for the quarter that ended in Dec. 2020 was $-4.5 Mil. It means GenMark Diagnostics's Accounts Receivable increased by $4.5 Mil from Sep. 2020 to Dec. 2020 .
GenMark Diagnostics's change in receivables for the fiscal year that ended in Dec. 2020 was $-4.1 Mil. It means GenMark Diagnostics's Accounts Receivable increased by $4.1 Mil from Dec. 2019 to Dec. 2020 .
GenMark Diagnostics's Accounts Receivable for the quarter that ended in Dec. 2020 was $20.8 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. GenMark Diagnostics's Days Sales Outstanding for the three months ended in Dec. 2020 was 37.88.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. GenMark Diagnostics's liquidation value for the three months ended in Dec. 2020 was $25.1 Mil.
The historical data trend for GenMark Diagnostics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMark Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -2.25 | -1.56 | -0.88 | -5.58 | -4.11 |
GenMark Diagnostics Quarterly Data | ||||||||||||||||||||
Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
Change In Receivables | Get a 7-Day Free Trial | -6.58 | -8.98 | 7.11 | 2.24 | -4.48 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMark Diagnostics (NAS:GNMK) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
GenMark Diagnostics's Days Sales Outstanding for the quarter that ended in Dec. 2020 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 20.79 | / | 50.08 | * | 91 |
= | 37.88 |
2. In Ben Graham's calculation of liquidation value, GenMark Diagnostics's accounts receivable are only considered to be worth 75% of book value:
GenMark Diagnostics's liquidation value for the quarter that ended in Dec. 2020 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 128.154 | - | 129.336 | + | 0.75 * 20.79 | + | 0.5 * 21.323 |
= | 25.1 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of GenMark Diagnostics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Tyler Jensen | officer: SVP, Engineering and Tech Dev | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Christine Shaw | officer: VP, Assay Development | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Alan Baer Maderazo | officer: VP, Qual, Reg, & Clin Affairs | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael Gleeson | officer: SVP, Corp. Accounts | 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008 |
Sarah Hollis Winkler | officer: VP, Human Resources | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael John Harkins | officer: SVP, Sales | 5964 LA PLACE COURT CARLSBAD CA 92008 |
John Frederick Ek | officer: Chief Financial Officer | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Scott Mendel | director, officer: President & CEO | 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008 |
Eric Stier | officer: SVP & General Counsel | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Brian Andrew Mitchell | officer: SVP, Operations | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Daryl Faulkner | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Michael Kagnoff | director | DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121 |
Lisa M. Giles | director | DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606 |
Kevin C Oboyle | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
James Fox | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 08-14-2020
By Marketwired Marketwired • 05-28-2020
By Marketwired Marketwired • 12-29-2020
By GlobeNewswire GlobeNewswire • 10-14-2020
By Marketwired Marketwired • 09-15-2020
By GuruFocus Research GuruFocus Editor • 01-26-2021
By Marketwired Marketwired • 07-30-2020
By Marketwired Marketwired • 06-29-2020
By Marketwired Marketwired • 05-12-2020
By Marketwired Marketwired • 01-12-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.